MedTrace Logo

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2011-11-24

No results posted yet for this study

Summary

The primary objective is to determine the efficacy of AKR963 compared to placebo and active comparator in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 1500 mg/dL.

Conditions

Interventions

DRUG

AKR-963

3600mg/day in capsules of AKR-963, Placebo, or Active Comparator

Sponsors & Collaborators

  • Trygg Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Kevin C Maki, PhD · Addison, Illinois Recruiting

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01229566 on ClinicalTrials.gov